| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.010 | AlteredExpression | disease | BEFREE | After adjusting for anthropometric factors; family history of diabetes; biochemical parameters including C-reactive protein, A1C, and fasting glucose and postload 2-h glucose levels; and the use of lipid-lowering medications, the hazard risks of diabetes development were 1.23 (95% CI 1.06-1.42), 1.26 (1.04-1.54), and 1.60 (1.30-1.96), respectively, in the prehypertension, stage 1 hypertension, and stage 2 hypertension groups. | 25986660 | 2015 | ||||
|
0.010 | Biomarker | disease | BEFREE | Circulating levels of total (CD31(+)/CD42a(-)) and activated (CD62E(+)) microparticles released by endothelial cells were significantly decreased (∼40% for both) after a 6-mo supervised aerobic exercise training program in individuals with prehypertension. | 26024684 | 2015 | ||||
|
0.010 | GeneticVariation | disease | BEFREE | The AGT and the GNB3 polymorphisms and insulin resistance in prehypertension. | 24722130 | 2014 | ||||
|
0.010 | GeneticVariation | disease | BEFREE | 472 healthy, normotensive subjects [normotension (NT) group], 454 prehypertensive subjects [prehypertension (PH) group] and 978 hypertensive patients [essential hypertension (EH) group] were screened for an association study between 5'-UCR -1248 A>G of Mfn2/HSG and hypertension by polymerase chain reaction and DNA sequencing after venous blood was drawn and DNA was extracted. | 23549803 | 2013 | ||||
|
0.010 | GeneticVariation | disease | BEFREE | The common AGTR1 A1166C (rs5186) polymorphism in the 3'-UTR region, particularly the presence of the 1166C allele, which fails to downregulate gene expression, predicted greater likelihood of being in the prehypertension group and higher SBP. | 20864943 | 2011 | ||||
|
0.010 | Biomarker | disease | BEFREE | These findings indicate that at the stage of pre-hypertension a disturbance in the ANF-c-GMP regulatory pathway may occur, which is expressed primarily at the circulatory rather than the renal excretory level. | 8777468 | 1996 |